title: Phospholipid-chitosan hybrid nanoliposomes promoting cell entry for drug delivery against cervical cancer.
abstract: This study emphasizes the development of a novel surface modified liposome as an anticancer drug nanocarrier. Quaternized N,O-oleoyl chitosan (QCS) was synthesized and incorporated into liposome vesicles, generating QCS-liposomes (Lip-QCS). The Lip-QCS liposomes were spherical in shape (average size diameter 171.5±0.8nm), with a narrow size distribution (PDI 0.1±0.0) and zeta potential of 11.7±0.7mV. In vitro mucoadhesive tests indicated that Lip-QCS possesses a mucoadhesive property. Moreover, the presence of QCS was able to induce the cationic charge on the surface of liposome. Cellular internalization of Lip-QCS was monitored over time, with the results revealing that the cell entry level of Lip-QCS was elevated at 24h. Following this, Lip-QCS were then employed to load cisplatin, a common platinum-containing anti-cancer drug, with a loading efficiency of 27.45±0.78% being obtained. The therapeutic potency of the loaded Lip-QCS was investigated using a 3D spheroid cervical cancer model (SiHa) which highlighted their cytotoxicity and apoptosis effect, and suitability as a controllable system for sustained drug release. This approach has the potential to assist in development of an effective drug delivery system against cervical cancer.
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Somsak
authors.initials: S
authors.lastname: Saesoo
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Suphawadee
authors.initials: S
authors.lastname: Bunthot
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Warayuth
authors.initials: W
authors.lastname: Sajomsang
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Pattarapond
authors.initials: P
authors.lastname: Gonil
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Sarunya
authors.initials: S
authors.lastname: Phunpee
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Patsaya
authors.initials: P
authors.lastname: Songkhum
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Kritapas
authors.initials: K
authors.lastname: Laohhasurayotin
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Tuksadon
authors.initials: T
authors.lastname: Wutikhun
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Teerapong
authors.initials: T
authors.lastname: Yata
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
authors.forename: Uracha Rungsardthong
authors.initials: UR
authors.lastname: Ruktanonchai
authors.affiliation: National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand. Electronic address: nattika@nanotec.or.th.
authors.forename: Nattika
authors.initials: N
authors.lastname: Saengkrit
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D048271:Chitosan / Q000737:chemistry*; D002945:Cisplatin / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D008081:Liposomes / Q000737:chemistry; D015394:Molecular Structure; D049329:Nanostructures / Q000737:chemistry*; D010743:Phospholipids / Q000737:chemistry*; D013329:Structure-Activity Relationship; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D010743:Phospholipids; D048271:Chitosan; D002945:Cisplatin
keywords: Cervical cancer; Liposome; Mucoadhesive nanoparticle; Targeted cancer therapy